FI101377B1 - Menetelmä N-alkyloitujen 1,4-dihydropyridiiniyhdisteiden valmistamiseksi - Google Patents

Menetelmä N-alkyloitujen 1,4-dihydropyridiiniyhdisteiden valmistamiseksi

Info

Publication number
FI101377B1
FI101377B1 FI911700A FI911700A FI101377B1 FI 101377 B1 FI101377 B1 FI 101377B1 FI 911700 A FI911700 A FI 911700A FI 911700 A FI911700 A FI 911700A FI 101377 B1 FI101377 B1 FI 101377B1
Authority
FI
Finland
Prior art keywords
alkylated
preparation
dihydropyridine compounds
haemorheological
drugs
Prior art date
Application number
FI911700A
Other languages
English (en)
Swedish (sv)
Other versions
FI911700A (fi
FI911700A0 (fi
FI101377B (fi
Inventor
Otto Behner
Hartmut Wollweber
Bruno Rosen
Siegfried Zaiss
Siegfried Goldmann
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of FI911700A0 publication Critical patent/FI911700A0/fi
Publication of FI911700A publication Critical patent/FI911700A/fi
Application granted granted Critical
Publication of FI101377B1 publication Critical patent/FI101377B1/fi
Publication of FI101377B publication Critical patent/FI101377B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Lubricants (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI911700A 1990-04-11 1991-04-09 Menetelmä N-alkyloitujen 1,4-dihydropyridiiniyhdisteiden valmistamisek si FI101377B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4011695A DE4011695A1 (de) 1990-04-11 1990-04-11 Verwendung von n-alkylierten 1,4-dihydropyridindicarbonsaeureestern als arzneimittel, neue verbindungen und verfahren zu ihrer herstellung
DE4011695 1990-04-11

Publications (4)

Publication Number Publication Date
FI911700A0 FI911700A0 (fi) 1991-04-09
FI911700A FI911700A (fi) 1991-10-12
FI101377B1 true FI101377B1 (fi) 1998-06-15
FI101377B FI101377B (fi) 1998-06-15

Family

ID=6404197

Family Applications (1)

Application Number Title Priority Date Filing Date
FI911700A FI101377B (fi) 1990-04-11 1991-04-09 Menetelmä N-alkyloitujen 1,4-dihydropyridiiniyhdisteiden valmistamisek si

Country Status (18)

Country Link
US (2) US5234935A (fi)
EP (1) EP0451654B1 (fi)
JP (1) JP3012352B2 (fi)
KR (1) KR0180741B1 (fi)
AT (1) ATE111079T1 (fi)
AU (1) AU642992B2 (fi)
CA (1) CA2040062A1 (fi)
DE (2) DE4011695A1 (fi)
DK (1) DK0451654T3 (fi)
ES (1) ES2063998T3 (fi)
FI (1) FI101377B (fi)
HU (2) HUT59905A (fi)
IE (1) IE64452B1 (fi)
IL (1) IL97796A (fi)
NZ (1) NZ237722A (fi)
PT (1) PT97300B (fi)
TW (1) TW197423B (fi)
ZA (1) ZA912652B (fi)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4342196A1 (de) * 1993-12-10 1995-06-14 Bayer Ag Neue 4-Phenyl-substituierte 1,4-Dihydropyridine
DE4125271A1 (de) * 1991-07-31 1993-02-11 Bayer Ag Neue n-alkylierte 1,4-dihydropyridindicarbonsaeureester
WO1993006082A1 (en) * 1991-09-13 1993-04-01 Merck & Co., Inc. Process for the preparation of 4-substituted-1,4-dihydropyridines
US5310917A (en) * 1991-09-13 1994-05-10 Merck & Co., Inc. Process for the preparation of 4-substituted-1,4-dihydropydrines
DE4133257A1 (de) * 1991-10-08 1993-04-15 Bayer Ag N-methyl-nimodipin, verfahren zu seiner herstellung und seine verwendung als zerebraltherapeutikum
DE4200714A1 (de) * 1992-01-14 1993-07-15 Bayer Ag Spezieller 1,4-dihydropyridin-3,5-dicarbonsaeureester, verfahren zu seiner herstellung und seine pharmazeutische verwendung
DE4223867A1 (de) * 1992-07-20 1994-01-27 Bayer Ag Spezieller 1,4-Dihydropyridin-3,5-dicarbonsäureester, Verfahren zu seiner Herstellung und seine pharmazeutische Verwendung
DE4313691A1 (de) * 1993-04-27 1994-11-03 Bayer Ag 2,6-Disubstituierte 4-Chinolyl-dihydropyridine
DE4313697A1 (de) * 1993-04-27 1994-11-03 Bayer Ag Chinolyl-dihydropyridinester, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimitteln
DE4313692A1 (de) * 1993-04-27 1994-11-03 Bayer Ag 3-Chinolyl substituierte Dihydropyridine, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimitteln
DE4328884A1 (de) * 1993-08-27 1995-03-02 Bayer Ag Verwendung von N-alkylierten 1,4-Dihydropyridincarbonsäureestern als Arzneimittel
PT657432E (pt) * 1993-12-10 2003-07-31 Bayer Ag 1,4-di-hidropiridinas fenil-substituidas com actividade cerebral
EE03192B1 (et) * 1993-12-10 1999-06-15 Bayer Aktiengesellschaft Isopropüül-(2-metoksüetüül)-4-(2-kloro-3-tsüanofenüül)-1,4-dihüdro-2,6-dimetüülpüri diin-3,5-dikarboksülaat, selle enantiomeerid ja vaheühend, meetodid nimetatud ühendite valmistamiseks ja kasutamine
DE4430094A1 (de) * 1994-08-25 1996-02-29 Bayer Ag Verwendung von 3,5-Dicarbonsäureester-1,4-Dihydropyridinen als Arzneimittel
DE19638570A1 (de) * 1996-09-20 1998-03-26 Bayer Ag Wirkstoffhaltige thermoplastische Polyurethane
WO2003053930A1 (en) * 2001-12-20 2003-07-03 Bayer Healthcare Ag 1,4-dihydro-1,4-diphenylpyridine derivatives
US8420790B2 (en) 2009-10-30 2013-04-16 Reliable Biopharmaceutical Corporation Efficient and scalable process for the manufacture of Fondaparinux sodium
EP2782573B1 (en) * 2011-11-24 2019-10-09 Richter Gedeon Nyrt. 1,4-dihydropyridine derivatives with hsp modulating activity

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1813436C3 (de) * 1968-12-07 1979-01-11 Bayer Ag, 5090 Leverkusen N-Substituierte 2,6-Dimethyl-l,4dihydropyridine
US3883543A (en) * 1969-05-10 1975-05-13 Bayer Ag N-alkyl-1,4-dihydropyridines
DE1923990C3 (de) * 1969-05-10 1978-11-23 Bayer Ag Verfahren zur Herstellung von N-substituierten M-Dihydropyridin-S.S-dicarbonsäureestern
DE1963188A1 (de) * 1969-12-17 1971-06-24 Bayer Ag Neue Cyanphenyl-1,4-dihydropyridinderivate
CH550189A (de) * 1971-01-08 1974-06-14 Ciba Geigy Ag Verfahren zur herstellung von neuen dibenzo (b,f) thiepincarbonsaeuren.
DE2210667A1 (de) * 1972-03-06 1973-09-20 Bayer Ag Kondensiert aromatisch substituierte 1,4-dihydropyridine, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DE2210672C3 (de) * 1972-03-06 1980-03-20 Bayer Ag, 5090 Leverkusen N-substituierte unsymmetrische 1 ^-Dihydropyridin-S^-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
DE2228377A1 (de) * 1972-06-10 1974-01-03 Bayer Ag Dihydropyridin-carbonsaeureamide, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
CH569043A5 (fi) * 1973-01-23 1975-11-14 Ciba Geigy Ag
US3956341A (en) * 1974-02-21 1976-05-11 Smithkline Corporation 1,3,5-Tricarbo-1,4-dihydropyridines
SU798099A1 (ru) * 1978-03-06 1981-01-23 Ордена Трудового Красного Знамениинститут Органического Синтезаан Латвийской Ccp 1-Бензил-2,6-диметил-4-о-или-M-НиТРОфЕНил-3,5-диэТОКСиКАРбОНил- 1,4-дигидРОпиРидиНы, пРО Вл ющиЕКОРОНАРОдилАТиРующую АКТиВНОСТь
EP0176956B1 (de) * 1984-09-28 1994-06-15 Byk Gulden Lomberg Chemische Fabrik GmbH Neue Diarylverbindungen
US4975440A (en) * 1984-09-28 1990-12-04 Byk Gulden Lomberg Chemische Fabrik Gmbh Optically-active 1,4-dihydropyridine
US4780538A (en) * 1986-02-12 1988-10-25 Merck & Co., Inc. Process for 1,4-dihydropyridine compounds using a titanamine catalyst
GB8616047D0 (en) * 1986-07-01 1986-08-06 Sandoz Ltd A 1 4-dihydropyridine derivatives
GR1002248B (en) * 1988-03-08 1996-04-23 Egyt Gyogyszervegyeszeti Gyar 1,4-dihydropyridine derivatives preparation method

Also Published As

Publication number Publication date
EP0451654A3 (en) 1992-07-08
ZA912652B (en) 1992-01-29
EP0451654A2 (de) 1991-10-16
IL97796A0 (en) 1992-06-21
AU7425391A (en) 1991-10-17
ES2063998T3 (es) 1995-01-16
DE4011695A1 (de) 1991-10-17
DK0451654T3 (da) 1995-02-13
IL97796A (en) 1995-03-15
PT97300A (pt) 1992-01-31
KR910018025A (ko) 1991-11-30
AU642992B2 (en) 1993-11-04
HU211313A9 (en) 1995-11-28
ATE111079T1 (de) 1994-09-15
DE59102788D1 (de) 1994-10-13
US5234935A (en) 1993-08-10
FI911700A (fi) 1991-10-12
NZ237722A (en) 1995-10-26
PT97300B (pt) 1998-10-30
FI911700A0 (fi) 1991-04-09
JP3012352B2 (ja) 2000-02-21
KR0180741B1 (ko) 1999-03-20
JPH04234847A (ja) 1992-08-24
EP0451654B1 (de) 1994-09-07
TW197423B (fi) 1993-01-01
FI101377B (fi) 1998-06-15
CA2040062A1 (en) 1991-10-12
US5432185A (en) 1995-07-11
HU911184D0 (en) 1991-10-28
IE911200A1 (en) 1991-10-23
IE64452B1 (en) 1995-08-09
HUT59905A (en) 1992-07-28

Similar Documents

Publication Publication Date Title
FI101377B1 (fi) Menetelmä N-alkyloitujen 1,4-dihydropyridiiniyhdisteiden valmistamiseksi
ATE82121T1 (de) Arzneimittel fuer die therapeutische behandlung von alopezie.
DE69630479D1 (de) Arzneimittel zur Behandlung von entzündlichen Herzkrankheiten
RU94041223A (ru) Средство для лечения мотонейроновых заболеваний
EP2269648A3 (de) Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
ES2137948T3 (es) Sistema avanzado de administracion de medicamentos y metodo de tratamiento de trastornos psiquiatricos, neurologicos y otros con carbamacepina.
ATE334668T1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
RU92016463A (ru) Применение производных цистина для изготовления лекарственных препаратов с иммуномоделирующим действием, фармацевтические композиции на их основе
IT8322855A0 (it) Composizione farmaceutica per la cura delle arteriopatie periferiche.
RU93045145A (ru) Замещенные производные циклогексана и их применение для лечения заболеваний, содержащее их лекарственное средство
DK0412554T3 (da) Sustained-release-præparat til administration i hjernen
DE59010302D1 (de) R-(-)-1-(5-Hydroxyhexyl)-3-methyl-7-propylxanthin, Verfahren zu dessen Herstellung und diese Verbindung enthaltende Arzneimittel
DE69621786D1 (de) Aminotetralinderivat zur behandlung von herzkreislauferkrankung
DK0538690T3 (da) Arylquinolyl-substituerede 1,4-dihydropyridin-dicarboxylsyrederivater, fremgangsmåde til deres fremstilling af deres anvendelse i lægemidler
DE68901172D1 (de) (-)-2-pyrazolinverbindung, deren optischen aufspaltung und therapeutisches agens zur behandlung von zerebralen gefaesskrankheiten, diese verbindung als aktives ingredient enthaltend.
RU95101840A (ru) Сложные эфиры циклогексанола и содержащий их фармацевтический препарат
ATE56706T1 (de) 4-methoxyisophthalsaeurederivat mit pharmakologischer wirksamkeit gegen thromboembolische erkrankung und verfahren zu dessen herstellung.
ZA896464B (en) Use of 2-azabicyclo(2.2.2)octane-3-carboxylic acid derivatives for the production of medicinal products intended for the treatment of diseases resulting from impairment of the vascular wall as well as for disorders of the microcirculation
NO993126D0 (no) Anvendelse av benzoylalkyl-1,2,3,6-tetrahydropyridiner
AR002736A1 (es) Uso de ester 3-metil-5-etilico de acido 2,6-dimetil-4-(2,3-diclorofenil-1,4 -dihidropiridin-3,5-dicarboxilico (felodipina) para fabricar un medicamento ypreparacion farmaceutica para el tratamiento de la disfuncion cerebral.
KR890000089A (ko) 신장 질환 치료제
ITMI911206A0 (it) Formulazioni farmaceutiche per il trattamento di malattie periferiche vascolari
RU93004536A (ru) Лекарство для профилактики и терапии неврологических и психиатрических нарушений, возникающих при употреблении алкоголя
RU95116290A (ru) Применение 5-морфолино-3-(4-хлорбензилиденамин)-2-оксазолидинона, фармацевтическая композиция на его основе, способ лечения